Summary EUSA Pharma (UK) Ltd (EUSA), formerly Essex Bidco Ltd, is a pharmaceutical company that offers medicines for the treatment of side-effects in cancer therapy, abnormal movements in neurology, prevention of surgical site infection and emergency solutions, and cancer supportive care. Its product portfolio includes Caphosol for the prevention and treatment of oral mucositis; Collatamp, to prevent the risk of infection in surgery; Custodiol, used in organ transplantation; Fomepizole, used as an antidote in ethylene glycol poisoning; and Xenazine to cure movement disorders, besides pipeline products. EUSA has a distribution network and commercial partners in Asia, Europe, the Middle East, Latin America, and North and South Africa. EUSA is headquartered in Hemel Hempstead, Hertfordshire, the UK. EUSA Pharma (UK) Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year... Research Beam Model: Research Beam Product ID: 2637699 250 USD New
EUSA Pharma (UK) Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

EUSA Pharma (UK) Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : October   2017
  • Pages : 27
  • Publisher : GlobalData
 
 
 
Summary

EUSA Pharma (UK) Ltd (EUSA), formerly Essex Bidco Ltd, is a pharmaceutical company that offers medicines for the treatment of side-effects in cancer therapy, abnormal movements in neurology, prevention of surgical site infection and emergency solutions, and cancer supportive care. Its product portfolio includes Caphosol for the prevention and treatment of oral mucositis; Collatamp, to prevent the risk of infection in surgery; Custodiol, used in organ transplantation; Fomepizole, used as an antidote in ethylene glycol poisoning; and Xenazine to cure movement disorders, besides pipeline products. EUSA has a distribution network and commercial partners in Asia, Europe, the Middle East, Latin America, and North and South Africa. EUSA is headquartered in Hemel Hempstead, Hertfordshire, the UK.

EUSA Pharma (UK) Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
EUSA Pharma (UK) Ltd, Medical Devices Deals, 2011 to YTD 2017 9
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 11
EUSA Pharma Acquires Rights to Arcoral Tab from Arcoral Pharma 12
Essex Bidco Acquires Assets from Jazz Pharma 13
Venture Financing 15
EUSA Pharma Raises Funds in Venture Financing 15
Partnerships 16
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 16
Superna Life Sciences Enters into Distribution Agreement with EUSA Pharma 17
Licensing Agreements 18
EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 18
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 20
Acquisition 21
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 21
EUSA Pharma (UK) Ltd - Key Competitors 24
EUSA Pharma (UK) Ltd - Key Employees 25
EUSA Pharma (UK) Ltd - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Key Facts 2
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EUSA Pharma (UK) Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
EUSA Pharma (UK) Ltd, Medical Devices Deals, 2011 to YTD 2017 9
EUSA Pharma (UK) Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
EUSA Pharma Acquires commercialization rights to Isqette from APEIRON Biologics 11
EUSA Pharma Acquires Rights to Arcoral Tab from Arcoral Pharma 12
Essex Bidco Acquires Assets from Jazz Pharma 13
EUSA Pharma Raises Funds in Venture Financing 15
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 16
Superna Life Sciences Enters into Distribution Agreement with EUSA Pharma 17
EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 18
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 20
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 21
EUSA Pharma (UK) Ltd, Key Competitors 24
EUSA Pharma (UK) Ltd, Key Employees 25
EUSA Pharma (UK) Ltd, Subsidiaries 26
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter